title: Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial.
authors.forename: J P
authors.initials: JP
authors.lastname: Zarski
authors.forename: K
authors.initials: K
authors.lastname: Barange
authors.forename: C
authors.initials: C
authors.lastname: Souvignet
authors.forename: M
authors.initials: M
authors.lastname: Bertini
authors.forename: P
authors.initials: P
authors.lastname: Marcellin
authors.forename: A
authors.initials: A
authors.lastname: Tran
authors.forename: Y
authors.initials: Y
authors.lastname: Deugnier
authors.forename: P
authors.initials: P
authors.lastname: Couzigou
authors.forename: A
authors.initials: A
authors.lastname: Plages
authors.forename: P
authors.initials: P
authors.lastname: Ambroise-Thomas
mesh_terms: D000328:Adult; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D012709:Serum Albumin / Q000627:therapeutic use*; D001084:Vidarabine Phosphate / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D012709:Serum Albumin; C046912:lactosaminated serum albumin; D001084:Vidarabine Phosphate; D007372:Interferons